SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act
Date of Report (Date of earliest event reported): March 2, 2012
ALIMERA SCIENCES, INC.
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation)
|(Commission File No.)
||(IRS Employer Identification No.)|
6120 Windward Parkway
Alpharetta, Georgia 30005
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (678) 990-5740
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
||Entry into a Definitive Material Agreement. |
On March 2, 2012, Alimera Sciences, Inc. (Alimera) entered into a Manufacturing Services Agreement (the Agreement) with Flextronics Medical Sales and Marketing, Ltd.
(Flextronics). Under the Agreement, Flextronics will manufacture, at its location in Tijuana, Mexico, Alimeras proprietary inserter system (the Product) for use with ILUVIEN®, Alimeras sustained release intravitreal implant for the treatment of chronic diabetic macular edema.
Under the Agreement, Alimera will pay certain per Product unit prices based on regularly scheduled shipments of a minimum
number of Product units. The initial term of the Agreement expires on February 24, 2015. After the expiration of the initial term, the Agreement will automatically renew for separate but successive one-year terms unless either party provides
written notice to the other party that it does not intend to renew the Agreement at least eighteen (18) months prior to the end of the term. The Agreement may be terminated by either party under certain circumstances.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the full text of the
Agreement, a copy of which will be filed with the exhibits to Alimeras quarterly report on Form 10-Q for the quarter ending March 31, 2012.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|ALIMERA SCIENCES, INC.|
/s/ RICHARD S. EISWIRTH, JR.
||Richard S. Eiswirth, Jr.|
||Chief Operating Officer and Chief Financial Officer|
Dated: March 2, 2012